kabutan

TORII PHARMACEUTICAL CO., LTD., The Current Fiscal Year Ordinary Profit Revised Upward by 6%

Thu Oct 31, 2024 3:00 pm JST Earnings

4551 TORII PHARMACEUTICAL CO., LTD. 【J-GAAP】

Earnings Report

TORII PHARMACEUTICAL CO., LTD. <4551> [TSE-P] announced its financial results after the market closed on October 31st (15:00). The ordinary profit (non-consolidated) for the cumulative third quarter of the fiscal year ending December 2024 (January to September) expanded to 4.68 billion yen, an increase of 41.4% compared to the same period last year.

In addition, the full-year ordinary profit has been revised upward by 6.3%, from the previous forecast of 6.4 billion yen to 6.8 billion yen (compared to 5.3 billion yen in the previous period), increasing the growth rate from 20.6% to 28.1%.

Based on the full-year plan announced by the company after the upward revision, our estimate of the ordinary profit for the July to December period (second half) is expected to increase by 11.7%, from the previous forecast of 3.41 billion yen to 3.81 billion yen (compared to 3.76 billion yen in the same period of the previous year), turning to a 1.4% increase in the ordinary profit outlook.

In the most recent three-month period, from July to September (3Q), the ordinary profit decreased to 1.7 billion yen, a 4.0% decrease compared to the same period last year. The operating profit margin decreased from 12.7% in the same period last year to 10.1%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Jan - Sep, 2022 35,315 4,066 3,918 2,856 101.7 70.8 Oct 31, 2022 J-GAAP
Jan - Sep, 2023 39,132 3,211 3,315 2,368 84.3 62.5 Oct 31, 2023 J-GAAP
Jan - Sep, 2024 43,333 4,661 4,686 3,525 125.4 68.9 Oct 31, 2024 J-GAAP
YoY +10.7% +45.2% +41.4% +48.9% +48.8%

Guidance Update

Second Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul - Dec, 2024 Prev 32,391 3,159 3,415 2,579 91.7 60 Jul 31, 2024 J-GAAP
Jul - Dec, 2024 New 32,891 3,559 3,815 2,879 102.4 60 Oct 31, 2024 J-GAAP
Revision Rate +1.5% +12.7% +11.7% +11.6% +11.6%

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2024 Prev 60,700 6,300 6,400 4,800 170.8 120 Jul 31, 2024 J-GAAP
Dec, 2024 New 61,200 6,700 6,800 5,100 181.4 120 Oct 31, 2024 J-GAAP
Revision Rate +0.8% +6.3% +6.3% +6.3% +6.2%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul - Dec, 2023 28,939 3,525 3,764 3,033 108.0 70 Feb 9, 2024 J-GAAP
Jul - Dec, 2024 Guidance 32,891 3,559 3,815 2,879 102.4 60 Oct 31, 2024 J-GAAP
YoY +13.7% +1.0% +1.4% -5.1% -5.1%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2022 48,896 5,540 5,537 3,944 140.4 100 Feb 10, 2023 J-GAAP
Dec, 2023 54,638 5,035 5,307 4,119 146.6 120 Feb 9, 2024 J-GAAP
Dec, 2024 Guidance 61,200 6,700 6,800 5,100 181.4 120 Oct 31, 2024 J-GAAP
YoY +12.0% +33.1% +28.1% +23.8% +23.8%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2023 13,433 1,701 1,772 1,282 45.6 12.7 Oct 31, 2023 J-GAAP
Oct - Dec, 2023 15,506 1,824 1,992 1,751 62.3 11.8 Feb 9, 2024 J-GAAP
Jan - Mar, 2024 13,451 1,383 1,166 878 31.3 10.3 Apr 26, 2024 J-GAAP
Apr - Jun, 2024 14,858 1,758 1,819 1,343 47.8 11.8 Jul 31, 2024 J-GAAP
Jul - Sep, 2024 15,024 1,520 1,701 1,304 46.4 10.1 Oct 31, 2024 J-GAAP
YoY +11.8% -10.6% -4.0% +1.7% +1.7%

Related Articles